Merging models of hepatitis C virus pathogenesis

Seminars in Liver Disease

Volumn 25, Issue 1, 2005, Pages 84-92

  Tillmann, Hans L ^b   Manns, Michael P ^a   Rudolph, K Lenhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

Cirrhosis; Fibrogenesis model; Fibrosis; HCV; Telomere model

Indexed keywords

ALBUMIN;

ALBUMIN BLOOD LEVEL; APOPTOSIS; CELL ACTIVATION; CELL AGING; CELL DAMAGE; CELL FUNCTION; DISEASE COURSE; FIBROGENESIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER REGENERATION; LIVER SINUSOID; NONHUMAN; ONSET AGE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STELLATE CELL; TELOMERE;

EID: 14644435700     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-864784     Document Type: Review

References (88)

1. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-1500
2. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med 1992;327:1899-1905
3. Tong MJ, el-Farra NS, Reikes AR. Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466
4. Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-96
5. Rodger AJ, Roberts S, Lanigan A, et al. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. Hepatology 2000;32:582-587
6. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233
7. Rai R, Wilson LE, Astemborski J, et al. Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology 2002;35:1247-1255
8. Tillmann HL. Hepatitis C virus infection. N Engl J Med 2001;345:1426
9. Morgello S. The nervous system and hepatitis C virus. Semin Liver Dis; 2005;25:118-121
10. Ockenga J, Tillmann HL, Trautwein C, et al. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 1997;27:18-24
11. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997;350:1425-1431
12. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611
13. Dore GJ, Thomas DL. Management and treatment of injection drug users with hepatitis C virus (HCV) monoinfection and HCV/human immunodeficiency virus coinfection. Semin Liver Dis 2005;25:8-32
14. Bräu N. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin. Semin Liver Dis 2005;25:33-51
15. Brau N, Rodriguez-Torres M, Salvatore M, et al. Control of HIV viral load through highly active antiretroviral therapy (HAART) slows down liver fibrosis progression in HIV/ HCV-coinfection and makes it the same as in HCV-monoinfection. The Puerto Rico-New York Hepatitis C Study Group. J Hepatol 2004. In press
16. Castellino S, Lensing S, Riely C, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort. Blood 2004;103:2460-2466
17. Vogt M, Lang T, Frosner G, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870
18. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004;12:96-102
19. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313
20. Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology 2003;38:1289-1296
21. Heller T, Rehermann B. Acute hepatitis C: a multifaceted disease. Semin Liver Dis 2005;25:7-17
22. Peters MG, Terrault NA. Alcohol use and hepatitis C. Hepatology 2002;36:S220-S225
23. Hezode C, Lonjon I, Roudot-Thoraval F, et al. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003;17:1031-1037
24. Pessione F, Ramond MJ, Njapoum C, et al. Cigarettte smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001;34:121-125
25. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832
26. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002;36(suppl 1):S46-S56
27. Pradat P, Voirin N, Tillmann HL, Fazly T, Chevallier M, Trepo C. Progression to cirrhosis: an age-dependent process. Hepatology 2004:40, In press
28. Poynard T, Radziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-739
29. Ryder SD. Trent Hepatitis C Study Group. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451-455
30. Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV - recipients. Transplantation 2004;77:1834-1842
31. Neumann UP, Berg T, Bahra M, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004;77:226-231
32. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210
33. Machicao VI, Bonatti H, Krishna M, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92
34. Paradis V, Mathurin P, Laurent A, et al. Histological features predictive of liver fibrosis in chronic Hepatitis C infection. J Clin Pathol 1996;49:1-7
35. Ghany MG, Kleiner DE, Alter HJ, et al. Progression of fibrosis in early stages of chronic hepatitis C. Hepatology 2000;32:496A
36. Yano M, Kumada H, Kage M, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340
37. Monto A, Patel K, Bostrom A, et al. Risks of a range of alcohol intake on hepatitis C-related fibrosis. Hepatology 2004;39:826-834
38. Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94
39. Hickman IJ, Powell EE, Prins JB, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003;39:1042-1048
40. André P, Perlemuter G, Budkowska A, Bréchet C, Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis 2005;25:93-104
41. Kleiner DE. The liver biopsy in chronic hepatitis C: A view from the other side of the microscope. Semin Liver Dis 2005;25:52-64
42. Powel EE, Edwards-Smith CJ, Hay JL, et al. Host genetic factors influence disease progression chronic hepatitis C. Hepatology 2000;31:828-833
43. Sonzogni L, Silvestri L, De Silvestri A, et al. Polymorphisms of microsomal epoxide hydrolase gene and severity of HCV-related liver disease. Hepatology 2002;36:195-201
44. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003;52:1206-1210
45. Akuta N, Chayama K, Suzuki F, et al. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 allele. J Med Virol 2001;64:109-116
46. Promrat K, McDermott DH, Gonzalez CM, et al. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology 2003;124:352-360
47. Muhlbauer M, Bosserhoff AK, Hartmann A, et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology 2003;125:1085-1093
48. Rojkind M, Greenwel P. Pathophysiology of liver fibrosis. In: Arias IM, Boyer JL, Chisari FV, et al, eds. The Liver Biology and Pathobiology, 4th ed. 2001:722-738
49. Freidman SL. Liver fibrosis - from bed to bedside. J Hepatol 2003;38:S38-S53
50. Friedman SL. Cytokines and fibrogenesis. Semin Liver Dis 1999;19:129-140
51. Greenwel P, Dominguez-Rosales JA, Mavi G, et al. Hydrogen peroxide: a link between acetaldehyde-elicited alpha1(I) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology 2000;31:109-116
52. Canbay A, Taimr P, Torok N, et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003;83:655-663
53. Canbay A, Feldstein AE, Higuchi H, et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003;38:1188-1198
54. Bataller R, Paik YH, Lindquist JN, et al. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004;126:529-540
55. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003;10:S59-S67
56. Buck M, Kim DJ, Houglum K, et al. C-Myb modulates transcription of α-smooth-muscle actin gene in activated hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2000;278:G321-G328
57. Lee KS, Buck M, Houglum K, et al. Activation of hepatic stellate cells by TGFβ and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995;96:2461-2468
58. Hellerbrand C, Jobin C, Licato LL, et al. Cytokines induce NF-κB in activated but not quiescent rat hepatic stellate cells. Am J Physiol 1998;275:G269-G278
59. Rippe RA, Almounajed G, Brenner DA. SP1 binding activity increases in activated Ito cells. Hepatology 1995;22:241-251
60. Stefanovic B, Hellerbrand C, Holcik M, et al. Posttranscriptional regulation of collagen alpha1(I) mRNA in hepatic stellate cells. Mol Cell Biol 1997;17:5201-5209
61. Rudolph KL, DePinho RA. Telomeres and telomerase in experimental liver cirrhosis. In: Arias IM, Boyer JL, Chisari FV, et al. eds. The Liver Biology and Pathobiology, 4th ed. 2001:1001-1010
62. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-573
63. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell 1999;97:503-514
64. Lundblad V. The end replication problem: more than one solution. Nat Med 1997;3:1198-1199
65. Greider CW, Blackburn EH. A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis. Nature 1989;337:331-337
66. Meyerson M, Counter CM, Eaton EN, et al. hEST2, the putative human telomerase catalytic subunit gene, is upregulated in tumor cells and during immortalization. Cell 1997;90:785-795
67. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277:955-959
68. Nakayama J, Tahara H, Tahara E, et al. Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 1998;18:65-68
69. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460
70. Wright WE, Shay JW. The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 1992;27:383-389
71. Dimri GP, Campisi J. Molecular and cell biology of replicative senescence. Cold Spring Harb Symp Quant Biol 1994;59:67-73
72. Wege H, Le HT, Chui MS, et al. Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology 2003;124:432-444
73. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of lifespan by introduction of telomerase into normal human cells. Science 1998;279:349-352
74. Lechel A, Manns MP, Rudolph KL. Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J Hepatol 2004;41:491-497
75. Wiemann SU, Satyanarayana A, Tsahuridu M, et al. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002;16:935-942
76. Livni N, Eid A, Ilan Y, et al. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995;75:2420-2426
77. Albrecht JH, Meyer AH, Hu MY. Regulation of cyclin-dependent-kinase inhibitor p21(WAF/Cip1/Sdi1) gene expression in hepatic regeneration. Hepatology 1997;25:557-563
78. Delhaye M, Louis H, Degraef C, et al. Relationship between hepatocyte proliferative activity and liver function reserve in human cirrhosis. Hepatology 1996;23:1003-1011
79. Delhaye M, Lousi H, Degraef C, et al. Hepatocyte proliferative activity in human liver cirrhosis. J Hepatol 1999;30:461-471
80. Kaita KD, Pettigrew N, Minuk GY. Hepatic regeneration in humans with various liver disease as assessed by Ki-67 staining of formalin-fixed paraffin-embedded liver tissue. Liver 1997;17:13-16
81. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997;91:25-34
82. Rudolph KL, Chang S, Millard M, et al. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000;287:1253-1258
83. Satyanarayana A, Wiemann SU, Buer J, et al. Telomere shortening impairs organ regeneration by inhibiting cell cycle re-entry of a subpopulation of cells. EMBO J 2003;22:4003-4013
84. Shelton DN, Chang E, Whittier PS. et al. Microarray analysis of replicative senescence. Curr Biol 1999;9:939-945
85. Schnabl B, Purbeck CA, Choi YH, et al. Replicative senescence of activated human hepatic stellate cells is accompanied by a pronounced inflammatory but less fibrogenic phenotype. Hepatology 2003;37:653-664
86. Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 2002;35:62-73
87. Issa R, Zhou X, Trim N, et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CC14-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J 2003;17:47-49
88. Sato R, Maesawa C, Fujisawa K, et al. Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis. Gut 2004;53:1001-1009